Louis88
liked
$Meta Platforms (FB.US)$ The 243 market fluctuated sideways today
Translated
1
Louis88
liked
$ContextLogic (WISH.US)$
Let's pack up our friends from Shigekura and line up on the balcony.
Let's pack up our friends from Shigekura and line up on the balcony.
Translated
3
Louis88
liked
$ContextLogic (WISH.US)$ 昨天挂单一堆,还好最后就买进来1股,笑死了
7
6
Louis88
liked
$Pfizer (PFE.US)$ Why the spike? I don’t understand why it went up to 5.83 this morning!?
9
2
Louis88
liked
$Tesla (TSLA.US)$ $Rivian Automotive (RIVN.US)$ $NIO Inc (NIO.US)$ $XPeng (XPEV.US)$On November 15, local time in the US, Rivian continued to soar 14.94% on the fourth trading day of its listing, and continued to soar close to 10% before the market on the 16th. The direct reason was that after the November 12 market, Rivian's announcement disclosed the company's insider transactions: Amazon COM INC, the shareholder of the company, who holds 10% of the company's shares, made a net purchase of 158 million shares on November 10 (the day of the IPO).
The US e-commerce giant Amazon, with a market capitalization of around 1.8 trillion US dollars, is Rivian's largest shareholder, with a shareholding ratio of more than 20%. Amazon and Kuroishi are the most important cornerstone investors in Rivian's IPOs. In total, they have subscribed to 5 billion US dollars of new shares, accounting for half of the newly issued new shares of more than 10 billion US dollars (135 million shares issued for 78 US dollars).
Therefore, the announced net purchase of 158 million shares by Amazon should include newly issued shares purchased as cornerstone investors, as well as shares held by other investors (this portion of the transaction price is not necessarily the issue price; similar to a bulk transaction). But no matter what, Amazon, which held more than 20% of its shares before the IPO, continues to weigh heavily...
The US e-commerce giant Amazon, with a market capitalization of around 1.8 trillion US dollars, is Rivian's largest shareholder, with a shareholding ratio of more than 20%. Amazon and Kuroishi are the most important cornerstone investors in Rivian's IPOs. In total, they have subscribed to 5 billion US dollars of new shares, accounting for half of the newly issued new shares of more than 10 billion US dollars (135 million shares issued for 78 US dollars).
Therefore, the announced net purchase of 158 million shares by Amazon should include newly issued shares purchased as cornerstone investors, as well as shares held by other investors (this portion of the transaction price is not necessarily the issue price; similar to a bulk transaction). But no matter what, Amazon, which held more than 20% of its shares before the IPO, continues to weigh heavily...
Translated
16
Louis88
liked
$Futu Holdings Ltd (FUTU.US)$ 这破逼玩意,最后 ,最后跌到60以下,不特么傻逼啊?
19
1
Louis88
liked
$Alibaba (BABA.US)$ bull and bear is fighting hard. Tmr is option closing. let’s see who will win the war
7
3
Louis88
liked
This bull market began on March 9, 2009 and is still going strong.
Check out what prices were on March 9, 2009 and what they are now.
$SPDR S&P 500 ETF (SPY.US)$: $68.11 Now: $468.53
$Invesco QQQ Trust (QQQ.US)$ : $25.74 Now: $398.60
$Dow Jones Industrial Average (.DJI.US)$: $65.44 Now: $363.30
$Netflix (NFLX.US)$: $5.50 Now $645.72
$Lululemon Athletica (LULU.US)$: $2.25 Now $467.91
$Regeneron Pharmaceuticals (REGN.US)$: $12.40 Now $611.54
So let the good times roll.
Check out what prices were on March 9, 2009 and what they are now.
$SPDR S&P 500 ETF (SPY.US)$: $68.11 Now: $468.53
$Invesco QQQ Trust (QQQ.US)$ : $25.74 Now: $398.60
$Dow Jones Industrial Average (.DJI.US)$: $65.44 Now: $363.30
$Netflix (NFLX.US)$: $5.50 Now $645.72
$Lululemon Athletica (LULU.US)$: $2.25 Now $467.91
$Regeneron Pharmaceuticals (REGN.US)$: $12.40 Now $611.54
So let the good times roll.
72
4
Louis88
liked
BioNTech will announce its Q3 results at 8 am EST on November 9th. On November 1, Pfizer raised its forecast for the full-year COVID-19 vaccine revenue in collaboration with BioNTech to US$36 billion.
In addition, BioNTech previously raised its full-year sales forecast in Q2 from 12.4 billion euros to 15.9 billion euros. The market expects that BioNtech will once again raise its annual revenue forecast for the new crown vaccine.
According to Bloomberg data...
In addition, BioNTech previously raised its full-year sales forecast in Q2 from 12.4 billion euros to 15.9 billion euros. The market expects that BioNtech will once again raise its annual revenue forecast for the new crown vaccine.
According to Bloomberg data...
11